This article is more than 5 years old. Information may no longer be current.

Acucela’s Stargardt disease treatment gets European orphan designation

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The European Medicines Agency has issued orphan designation to emixustat for the treatment of Stargardt disease, Acucela announced in a press release.

Emixustat hydrochloride modulates the visual cycle by inhibiting RPE65 protein, a critical enzyme of the pathway, the release said.

The FDA granted orphan drug designation to emixustat in January 2017 for the treatment of Stargardt disease. The current designation from the EMA does not cover other possible indications for emixustat.